[go: up one dir, main page]

EA199700126A1 - Вакцина против гепатита в - Google Patents

Вакцина против гепатита в

Info

Publication number
EA199700126A1
EA199700126A1 EA199700126A EA199700126A EA199700126A1 EA 199700126 A1 EA199700126 A1 EA 199700126A1 EA 199700126 A EA199700126 A EA 199700126A EA 199700126 A EA199700126 A EA 199700126A EA 199700126 A1 EA199700126 A1 EA 199700126A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis
vaccine against
against hepatitis
proposed
combination
Prior art date
Application number
EA199700126A
Other languages
English (en)
Inventor
Пьер Озе
Натали Мари-Жозеф Клод Гаркон
Пьер Десмон
Original Assignee
Смитклайн Бичем Байолоджикалз, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10770292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199700126(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Смитклайн Бичем Байолоджикалз, С.А. filed Critical Смитклайн Бичем Байолоджикалз, С.А.
Publication of EA199700126A1 publication Critical patent/EA199700126A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предлагается новый препарат вакцины, содержащий компонент гепатита B, в частности поверхностный антиген гепатита B, в сочетании с фосфатом алюминия и 3-де-O-ацилированным монофосфориллипидом A.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199700126A 1995-02-25 1996-02-15 Вакцина против гепатита в EA199700126A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9503863.4A GB9503863D0 (en) 1995-02-25 1995-02-25 Vaccine compositions
PCT/EP1996/000681 WO1996026741A1 (en) 1995-02-25 1996-02-15 Hepatitis b vaccine

Publications (1)

Publication Number Publication Date
EA199700126A1 true EA199700126A1 (ru) 1998-02-26

Family

ID=10770292

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199700126A EA199700126A1 (ru) 1995-02-25 1996-02-15 Вакцина против гепатита в

Country Status (35)

Country Link
US (1) US5972346A (ru)
EP (1) EP0810877B1 (ru)
JP (1) JP3881015B2 (ru)
KR (1) KR100365373B1 (ru)
CN (1) CN1101225C (ru)
AP (1) AP766A (ru)
AR (1) AR002279A1 (ru)
AT (1) ATE209045T1 (ru)
AU (1) AU695921B2 (ru)
BG (1) BG101851A (ru)
BR (1) BR9607458A (ru)
CA (1) CA2212552C (ru)
CZ (1) CZ288417B6 (ru)
DE (1) DE69617211T2 (ru)
DK (1) DK0810877T3 (ru)
EA (1) EA199700126A1 (ru)
ES (1) ES2166879T3 (ru)
FI (1) FI118118B (ru)
GB (1) GB9503863D0 (ru)
HU (1) HU224832B1 (ru)
IL (1) IL117249A (ru)
MA (1) MA23814A1 (ru)
MX (1) MX9706450A (ru)
MY (1) MY113428A (ru)
NO (1) NO319394B1 (ru)
NZ (1) NZ302674A (ru)
OA (1) OA10612A (ru)
PL (1) PL182679B1 (ru)
PT (1) PT810877E (ru)
SA (1) SA96160633B1 (ru)
SK (1) SK115097A3 (ru)
TR (1) TR199700849T1 (ru)
TW (1) TW467745B (ru)
WO (1) WO1996026741A1 (ru)
ZA (1) ZA961460B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
JP2002532116A (ja) * 1998-12-23 2002-10-02 メルク エンド カムパニー インコーポレーテッド 改良された組換えｂ型肝炎表面抗原
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
US20090214592A1 (en) * 2005-02-16 2009-08-27 O'hagan Derek Adjuvant composition comprising aluminium phosphate and 3D-MPL
PL1909830T3 (pl) * 2005-08-02 2012-02-29 Novartis Vaccines And Diagnostics S R L Ograniczenie oddziaływania pomiędzy olejem w adiuwancie a środkiem powierzchniowo czynnym w antygenie
EP1945252B1 (en) 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
EP1951302A2 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CN100415294C (zh) * 2005-12-23 2008-09-03 中国农业大学 一种治疗和/或预防乙肝的药物
JP6087041B2 (ja) 2006-01-27 2017-03-08 ノバルティス アーゲー 血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
ES2480491T3 (es) 2006-12-06 2014-07-28 Novartis Ag Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ586439A (en) 2007-12-24 2012-10-26 Novartis Ag Method for peforming an immunodiffusion assay (SRID) for influenza hemagglutinin antigen based on desorbing the antigen from the aluminium adjuvant salt
ES2563730T3 (es) 2009-07-15 2016-03-16 Glaxosmithkline Biologicals S.A. Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
SI2707385T1 (en) 2011-05-13 2018-01-31 Glaxosmithkline Biologicals Sa Pregnant RSV F antigens
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
CN118987191A (zh) 2018-11-13 2024-11-22 变异生物技术公司 用于治疗乙型肝炎的免疫原性组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0414374T3 (da) * 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
DK0637223T3 (da) * 1991-05-29 1999-04-26 Origin Medsystems Inc Tilbageholdelsesanordning til endoskopisk kirurgi
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
EP0835663B1 (en) * 1992-05-23 2009-09-30 GlaxoSmithKline Biologicals S.A. Combined vaccines comprising Hepatitis B surface antigen and other antigens
ES2109685T5 (es) * 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
GB9311536D0 (en) * 1993-06-04 1993-07-21 Unilever Plc Hot soluble low density extractable food product

Also Published As

Publication number Publication date
AP766A (en) 1999-09-17
PL321966A1 (en) 1998-01-05
IL117249A0 (en) 1996-06-18
AU4878096A (en) 1996-09-18
FI973457L (fi) 1997-08-22
NO319394B1 (no) 2005-08-08
WO1996026741A1 (en) 1996-09-06
DK0810877T3 (da) 2002-02-25
EP0810877A1 (en) 1997-12-10
CZ288417B6 (en) 2001-06-13
NZ302674A (en) 1999-01-28
TR199700849T1 (xx) 1998-01-21
AP9701060A0 (en) 1997-10-31
MA23814A1 (fr) 1996-10-01
NO973873L (no) 1997-08-22
FI118118B (fi) 2007-07-13
SA96160633B1 (ar) 2005-10-15
AR002279A1 (es) 1998-03-11
US5972346A (en) 1999-10-26
IL117249A (en) 2000-11-21
DE69617211D1 (en) 2002-01-03
JPH11501018A (ja) 1999-01-26
JP3881015B2 (ja) 2007-02-14
OA10612A (en) 2002-08-29
BR9607458A (pt) 1998-06-30
KR19980702480A (ko) 1998-07-15
EP0810877B1 (en) 2001-11-21
MY113428A (en) 2002-02-28
CA2212552A1 (en) 1996-09-06
CA2212552C (en) 2006-07-11
DE69617211T2 (de) 2002-07-25
PL182679B1 (pl) 2002-02-28
ATE209045T1 (de) 2001-12-15
HUP9801242A1 (hu) 1998-08-28
ES2166879T3 (es) 2002-05-01
TW467745B (en) 2001-12-11
NO973873D0 (no) 1997-08-22
CZ267497A3 (cs) 1998-02-18
PT810877E (pt) 2002-04-29
KR100365373B1 (ko) 2003-07-07
CN1176604A (zh) 1998-03-18
ZA961460B (en) 1996-08-29
BG101851A (en) 1998-04-30
FI973457A0 (fi) 1997-08-22
CN1101225C (zh) 2003-02-12
MX9706450A (es) 1998-07-31
HU224832B1 (en) 2006-03-28
GB9503863D0 (en) 1995-04-19
HUP9801242A3 (en) 2000-08-28
HK1004117A1 (en) 1998-11-20
SK115097A3 (en) 1998-02-04
AU695921B2 (en) 1998-08-27

Similar Documents

Publication Publication Date Title
EA199700126A1 (ru) Вакцина против гепатита в
ES2129461T3 (es) Proteina hibrida entre cs de plasmodium y hbsag.
PT835663E (pt) Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios
NO976035D0 (no) Vaksinesammensetning omfattende et polyakkaridkonjugat antigen absorbert på aluminiumfosfat
AU9052091A (en) Vaccines based on hepatitis b surface antigen
EA199800946A1 (ru) Концентрированный препарат антител
ES2013226T3 (es) Una composicion que genera luz al activarse y su metodo de preparacion.
DE3673418D1 (de) Wirbelerzeuger fuer einlass.
IT8921515A0 (it) Procedimento per la preparazione di estratti ad alto contenuto in antocianosidi.
NO913309D0 (no) Fremgangsmaate for fremstilling av en aluminiumlegeringstrimmel med redusert rynking.
EA200000196A1 (ru) Универсальная плазма крови
FI880802A7 (fi) Hepatitis B-viruspinta-antigeenin esi-S-alueen T- ja B-soluepitoopit.
AP9100291A0 (en) Synthetic peptides and mixtures therof for detecting HIV antibodies.
DE4481026T1 (de) Kolbenverbrennungsmaschine mit begrenzter Ansaugung
IT8919649A0 (it) Pistone alleggerito.
ES2236703T3 (es) Uso de metodos para identificar oligopeptidos de señal hidrofilos.
EA200000069A1 (ru) Способ получения 4-замещенных-1h-индол-3-глиоксамидов
FI922786A7 (fi) Yhdistelmäkalvo, menetelmä sen valmistamiseksi ja sen käyttö
TR200003235T2 (tr) Yeni kompozisyon
KR890701743A (ko) B형 간염 표면 항원 백신
AU4964390A (en) Multicylinder self-starting uniflow engine
DE69006074D1 (de) Wirbelkammer-Dieselmotor.
EA200001076A1 (ru) Способ получения 4-замещенных-1h-индол-3-глиоксамидов
ITVI940028A0 (it) Pedale per biciclette e simili con funzione pompante
AU7909391A (en) Epitopes of the pre-s region of hepatitis b virus surface antigen